LIXTE BIOTECHNOLOGY HOLDINGS, INC.

LIXT Nasdaq CIK: 0001335105

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 433 PLAZA REAL, BOCA RATON, FL, 33432
Mailing Address 433 PLAZA REAL, BOCA RATON, FL, 33432
Phone 310 203 2902
Fiscal Year End 1231
EIN 202903526

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 31, 2026 View on SEC
8-K Current report of material events March 20, 2026 View on SEC
8-K Current report of material events March 10, 2026 View on SEC
8-K Current report of material events February 18, 2026 View on SEC
8-K Current report of material events December 31, 2025 View on SEC
4 Insider stock transaction report December 29, 2025 View on SEC
4 Insider stock transaction report December 29, 2025 View on SEC
8-K Current report of material events December 23, 2025 View on SEC
8-K Current report of material events December 22, 2025 View on SEC
424B5 Prospectus supplement December 19, 2025 View on SEC

Annual Reports

10-K March 31, 2026
  • Lead drug candidate LB-100 shows promise in treating aggressive cancers like Ovarian Clear Cell Carcinoma.
  • Strategic partnerships with groups like the Spanish Sarcoma Group help minimize clinical trial costs.
View Analysis

Material Events

8-K Strategy Change March 10, 2026
Medium Impact
  • Lixte and Orbit Capital restructured and clarified their partnership regarding Liora Technologies Europe Ltd., a crucial subsidiary for cancer treatment development.
  • Orbit Capital now holds a 20% ownership stake in Liora and 700,000 shares of Lixte's common stock, aligning its interests directly with Lixte's overall success.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.